The board overseeing Sanuwave's clinical study for its DermaPace diabetic foot ulcer treatment wants to see more data after determining the trial isn't likely to make its endpoint.
Sanuwave Health (OTC:SNWV) said the oversight board for a clinical trial of its DermaPace diabetic foot ulcer treatment wants more data after determining that the trial is unlikely to meet its primary endpoint.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1cw5BJl
Cap comentari:
Publica un comentari a l'entrada